Avantax Advisory Services, Inc. Cel Sci Corp Transaction History

Avantax Advisory Services, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 21, 2021	SELL	$7.64 - $12.49 $474,741 - $776,116	-62,139 Closed	0 $0
Q2 2021 Jul 29, 2021	SELL	$8.68 - $27.49 $535,764 - $1.7 Million	-61,724 Reduced 49.83%	62,139 $532,000
Q1 2021 May 13, 2021	BUY	$12.0 - $27.64 $47,808 - $110,117	3,984 Added 3.32%	123,863 $1.88 Million
Q4 2020 Jan 22, 2021	BUY	$11.05 - $16.62 $33,127 - $49,826	2,998 Added 2.57%	119,879 $1.4 Million
Q3 2020 Oct 14, 2020	BUY	$11.69 - $14.54 $176,881 - $220,004	15,131 Added 14.87%	116,881 $1.49 Million
Q2 2020 Aug 06, 2020	BUY	$9.75 - $17.6 $279,337 - $504,240	28,650 Added 39.19%	101,750 $1.5 Million
Q1 2020 Apr 30, 2020	BUY	$7.54 - $17.05 $551,174 - $1.25 Million	73,100 New	73,100 $862,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Avantax Advisory Services, Inc. with notifications on news.